Skip to main content

Articles

ASH 2018 - Chronic Lymphocytic Leukemia
Ibrutinib 7-Year Follow-Up Data in First-Line and Relapsed/Refractory Patients with CLL/SLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk CLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression-Free Survival Compared with Bendamustine plus Rituximab in Untreated Older Patients with CLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Results from the Phase 3 iLLUMINATE Study: Ibrutinib + Obinutuzumab as First-Line Treatment in Patients with CLL/SLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed/Refractory CLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
MURANO Study: The Impact of Minimal Residual Disease on Long-Term Clinical Outcomes After Venetoclax plus Rituximab
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
CLL Treatment Patterns, Dosing, and Sequencing: Interim Analysis Results from the Prospective informCLL Real-World Registry
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
The Combination of Ibrutinib with Anti-CD19 CAR T-Cells Shows a High Response Rate in the Treatment of CLL
Read More
Page 64 of 245
Results 631 - 640 of 2441